Enzo Biochem Stock Fundamentals
| ENZ Stock | USD 0.97 0.02 2.02% |
Enzo Biochem fundamentals help investors to digest information that contributes to Enzo Biochem's financial success or failures. It also enables traders to predict the movement of Enzo Stock. The fundamental analysis module provides a way to measure Enzo Biochem's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enzo Biochem stock.
At this time, Enzo Biochem's Selling And Marketing Expenses is fairly stable compared to the past year. Non Recurring is likely to rise to about 5.4 M in 2024, whereas Interest Expense is likely to drop slightly above 187.2 K in 2024. Enzo | Select Account or Indicator |
Enzo Biochem Company Operating Margin Analysis
Enzo Biochem's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Enzo Biochem Operating Margin | (0.39) % |
Most of Enzo Biochem's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enzo Biochem is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Enzo Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Enzo Biochem has an Operating Margin of -0.3875%. This is 98.9% lower than that of the Health Care Providers & Services sector and 99.39% lower than that of the Health Care industry. The operating margin for all United States stocks is 92.97% lower than that of the firm.
Enzo Biochem Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Enzo Biochem's current stock value. Our valuation model uses many indicators to compare Enzo Biochem value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Enzo Biochem competition to find correlations between indicators driving Enzo Biochem's intrinsic value. More Info.Enzo Biochem is rated # 5 in return on equity category among its peers. It also is rated # 5 in return on asset category among its peers . At this time, Enzo Biochem's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Enzo Biochem's earnings, one of the primary drivers of an investment's value.Enzo Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enzo Biochem's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enzo Biochem could also be used in its relative valuation, which is a method of valuing Enzo Biochem by comparing valuation metrics of similar companies.Enzo Biochem is currently under evaluation in operating margin category among its peers.
Enzo Fundamentals
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0744 | ||||
| Profit Margin | (0.82) % | ||||
| Operating Margin | (0.39) % | ||||
| Current Valuation | 2.71 M | ||||
| Shares Outstanding | 52.24 M | ||||
| Shares Owned By Insiders | 23.72 % | ||||
| Shares Owned By Institutions | 32.04 % | ||||
| Number Of Shares Shorted | 477.48 K | ||||
| Price To Earning | 26.60 X | ||||
| Price To Book | 0.92 X | ||||
| Price To Sales | 1.59 X | ||||
| Revenue | 31.91 M | ||||
| Gross Profit | 11.57 M | ||||
| EBITDA | (8.35 M) | ||||
| Net Income | (26.08 M) | ||||
| Cash And Equivalents | 82.37 M | ||||
| Cash Per Share | 0.44 X | ||||
| Total Debt | 3.51 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 2.21 X | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | (26.26 M) | ||||
| Short Ratio | 7.55 X | ||||
| Earnings Per Share | (0.19) X | ||||
| Target Price | 5.5 | ||||
| Number Of Employees | 125 | ||||
| Beta | 0.73 | ||||
| Market Capitalization | 50.68 M | ||||
| Total Asset | 85.76 M | ||||
| Retained Earnings | (294.43 M) | ||||
| Working Capital | 45.24 M | ||||
| Current Asset | 91.4 M | ||||
| Current Liabilities | 20.57 M | ||||
| Annual Yield | 0.41 % | ||||
| Net Asset | 85.76 M |
About Enzo Biochem Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enzo Biochem's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enzo Biochem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enzo Biochem based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 5.9 M | 3.7 M | |
| Total Revenue | 31.9 M | 63.1 M | |
| Cost Of Revenue | 17.3 M | 31.5 M | |
| Stock Based Compensation To Revenue | 0.07 | 0.08 | |
| Sales General And Administrative To Revenue | 0.76 | 0.44 | |
| Research And Ddevelopement To Revenue | 0.08 | 0.10 | |
| Capex To Revenue | 0.02 | 0.02 | |
| Revenue Per Share | 0.63 | 0.60 | |
| Ebit Per Revenue | (0.31) | (0.29) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Enzo Stock Analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.